Loading clinical trials...
Loading clinical trials...
A Phase Ib, Multi-center, Open-label, Dose-escalation Study of Oral LBH589 When Administered in Combination With Oral Lenalidomide & Dexamethasone in Adult Patients With Multiple Myeloma
Conditions
Interventions
LBH589
Lenalidomide
Locations
10
United States
UCSF Medical Center
San Francisco, California, United States
Emory University School of Medicine/Winship Cancer Institute Dept. of Winship Cancer Inst.
Atlanta, Georgia, United States
St. Vincent's Comprehensive Cancer Center
New York, New York, United States
Novartis Investigative Site
South Brisbane, Queensland, Australia
Novartis Investigative Site
Prahran, Victoria, Australia
Novartis Investigative Site
Lille, France
Start Date
April 22, 2008
Primary Completion Date
November 8, 2017
Completion Date
November 8, 2017
Last Updated
December 19, 2020
NCT06179888
NCT06152575
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions